NCT02452268终止1 期
A Phase 1 Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Ra)) Alone and in Combination With PDR001 in Adults With Metastatic Cancers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 83
- 试验地点
- 7
- 主要终点
- Assess the dose-limiting toxicity of the single agent NIZ985 and the combination of PDR001
研究概览
简要总结
Phase I/Ib multicenter clinical trial. Single agent dose escalation of NIZ985 followed by expansion. Second escalation of NIZ985 in combination with PDR001 followed by expansion
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed solid tumor malignancy that is metastatic or unresectable and have progressed on at least 1 prior therapy and for whom standard curative or palliative measures do not exist or are associated with minimal subject survival benefit.
- •Evaluable or measurable disease, defined as by Response Evaluation Criteria in Solid Tumors (RECIST).
- •Recovered to ≤ grade 1 NCI CTCAE version 4.0 from toxicity of prior chemotherapy or biologic therapy administered more than 4 weeks earlier.
- •Subjects on bisphosphonates for any cancer or on hormone therapy for prostate cancer may continue this therapy. However, subjects with prostate cancer must have confirmed metastatic disease that has progressed despite hormonal therapy producing castrate levels of testosterone.
- •Age ≥18 years.
- •ECOG performance status ≤1 (Karnofsky ≥70%).
- •Normal organ and marrow function:
- •leukocytes ≥3,000/mcL
- •absolute neutrophil count (ANC) ≥1,500/mcL
- •platelets ≥100,000/mcL
- •total bilirubin within normal institutional limits
- •AST/ALT ≤2.5 × ULN
- •creatinine <1.5 × institutional ULN OR
- •creatinine clearance ≥60 mL/min/1.73 m2 for subjects with serum creatinine levels >1.5 × higher than ULN.
- •DLCO/VA and FEV1 ≥ 50% of predicted on PFTs.
- •Subjects with inactive central nervous system (CNS) metastasis are eligible..
- •Women of child-bearing potential and men must agree to use adequate contraception prior to study entry, during the treatment portion of the study and for 4 months after completion of hetIL-15 administration.
- •Able to provide written informed consent.
- •Life expectancy > 3 months.
排除标准
- •Prior IL-15 treatment or cytotoxic therapy, immunotherapy, radiotherapy, major surgery, antitumor vaccines or monoclonal antibodies in the 4 weeks prior or for checkpoint inhibitors such as anti-CTLA-4 or anti PD1/PD-L1 or nitrosoureas or mitomycin C for 6 weeks prior to C1D
- •Primary brain cancers or active CNS metastases should be excluded from this clinical trial
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to hetIL-
- •Concurrent anticancer therapy (including other investigational agents) with the exception of hormone therapy for prostate cancer.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, cognitive impairment, active substance abuse, or psychiatric illness/social situations that, in the view of the Investigator, would preclude safe treatment or the ability to give informed consent and limit compliance with study requirements.
- •HIV positive patients.
- •Positive hepatitis B or C serology.
- •History of severe asthma or absolute requirement for chronic inhaled corticosteroid medications.
- •History of autoimmune disease, with the exception of an autoimmune event associated with prior ipilimumab (anti-CTLA-4) therapy that has been completely resolved for more than 4 weeks prior to C1D1.
研究组 & 干预措施
NIZ985
Experimental
- Single treatment arm, dose escalation administered subcutaneously (SC) on MWF for 2 consecutive weeks.
- Cycle length 28 days.
- Occurrence of a dose-limiting toxicity (DLT) leads to the expansion to 6 subjects.
- MTD is the dose prior to the dose level where ≥ 2/6 subjects have a DLT.
- Following identification of the MTD / RDE, dose expansion will follow.
干预措施: NIZ985 (Drug)
NIZ985 + PDR001
Experimental
- The phase Ib dose escalation portion of the study will consist of a fixed dose (400 mg, IV infusion, Q4W) of PDR001 and escalating doses of NIZ985 (hetIL-15) to evaluate safety, tolerability and determine the MTD and/or RDE of the combination to be used in expansion cohorts.
- On days when PDR001 and NIZ985 are administered on the same day, PDR001 will be administered first. NIZ985 will be administered after the PDR001 infusion has been completed.
- Information on the preparation and administration of PDR001 is found in the PDR001 pharmacy manual.
干预措施: PDR001 (Drug)
结局指标
主要结局
Assess the dose-limiting toxicity of the single agent NIZ985 and the combination of PDR001
时间窗: 28 days
次要结局
- Determine the pharmacokinetic (PK) profile of hetIL-15, including Cmax.(28 Days)
- Determine the maximum tolerated dose (MTD) of hetIL-15 as determined by DLTs during Cycle 1.(28 days)
- Determine the pharmacokinetic (PK) profile of hetIL-15, including T½(28 days)
- Determine the preliminary anti-tumor activity of hetIL-15(8 weeks)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
1 期
Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid TumorsAdvanced Solid TumorNCT05101109ABL Bio, Inc.24
招募中
1 期
This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid TumorsAdvanced Solid TumorNCT04762641ABL Bio, Inc.100
招募中
1 期
A Study With ABL103 in Subjects With Advanced or Metastatic Solid TumorsAdvanced Solid TumorNCT06126666ABL Bio, Inc.96
已完成
1 期
Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid TumorsHead and Neck Squamous Cell CarcinomaSolid TumorMelanomaNCT04096638invoX Pharma Limited61
已完成
1 期
A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid TumorsAdvanced Solid TumorNCT04116710Heat Biologics15